Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza vaccine GSK2186877A formulation 1 · 1 trial · 1 indication
Fever grade greater than or equal to 2 i.e. ≥ 2 was defined as axillary temperature \>38 degree centigrade (°C).
| Arm | Type | Description |
|---|---|---|
| Influenza vaccine GSK2186877A formulation 1 Group | EXPERIMENTAL | Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6. |
| Influenza vaccine GSK2186877A formulation 2 Group | EXPERIMENTAL | Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6. |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine GSK2186877A formulation 1 | BIOLOGICAL | Intramuscular administration, 2 doses |
| Influenza vaccine GSK2186877A formulation 2 | BIOLOGICAL | Intramuscular administration, 1 dose |
| Fluarix | BIOLOGICAL | Intramuscular administration, 1 dose |
Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol. * Children, male or female between, and includ...
Influenza vaccine GSK2186877A formulation 1 is an investigational vaccine being developed for the prevention of influenza. It is currently in Phase 1 clinical development and has been studied in healthy children aged 6 months and older. The vaccine is designed to elicit an immune response against influenza viruses.
Influenza vaccine GSK2186877A formulation 1 is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and immunogenicity of this vaccine candidate in pediatric populations.
Influenza vaccine GSK2186877A formulation 1 is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and immunogenicity in healthy children.
Influenza vaccine GSK2186877A formulation 1 has been evaluated in one completed Phase 1 clinical trial, identified as NCT01096056. This trial, titled 'Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children,' enrolled 40 participants in Spain and was a controlled, randomized study.
Yes, Influenza vaccine GSK2186877A formulation 1 is also known as GSK2186877A. The clinical trial NCT01096056 refers to the vaccine as GSK2186877A, and the formulation 1 designation specifies the particular version being tested. Both names refer to the same investigational influenza vaccine candidate.